Several medicines are poised to reach new heights after winning key endorsements from European drug regulators. | Among those ...
Unveiling the Future of Chronic Insomnia treatment – DelveInsight's latest report explores epidemiological insights and market opportunities spanning the 7MM. LAS VEGAS , NV, UNITED STATES, January 31 ...
RAHWAY, N.J. - Merck & Co ., Inc. (NYSE:MRK) has received a positive recommendation from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) for its pneumococcal ...
HonorHealth announced the creation of its new international Center for Translational Science. Sanofi said it will repurchase $5.2 billion of stock and grow profits faster this year as the drugmaker ...
Co., Inc. (NYSE:MRK), a global healthcare leader, declared on Monday a quarterly dividend and a substantial stock repurchase ...
Merck (MRK) announced that the board of directors has declared a quarterly dividend of 81c per share of the company’s common stock for the ...
The Phase III trial saw a clinically meaningful benefit in overall survival with a combination of Itovebi alongside Ibrance ...
A new study led by Western researchers found frequent treatment with intranasal oxytocin – a hormone in the brain associated ...
A new study led by researchers at Moffitt Cancer Center shows that asymptomatic brain metastasis is more common in stage 4 breast cancer patients than previously believed. The study, published in ...
Results have been announced from a Phase III trial of Merck & Co’s anti-PD-1 therapy Keytruda (pembrolizumab) plus Lenvima ...
The addition of lenvatinib and pembrolizumab to chemotherapy did not extend OS for certain patients with advanced ...